Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin-releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.
|Titolo:||Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass|
|Parole Chiave:||Bone mineral density; Gonadotropin-releasing hormone agonists; Osteopenia; Osteoporosis; Polycystic ovary syndrome|
|Settore Scientifico Disciplinare:||Settore MED/13 - Endocrinologia|
|Data di pubblicazione:||set-1997|
|Digital Object Identifier (DOI):||10.1007/BF03348007|
|Appare nelle tipologie:||01 - Articolo su periodico|